A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant

Authors:

Abstract
No abstract available
Funding Information
  • Cystic Fibrosis Trust
  • Cystic Fibrosis Foundation
  • NIHR Imperial Biomedical Research Centre
  • AbbVie
  • Vertex Pharmaceuticals Inc
  • Engineering and Physical Sciences Research Council
  • National Institute for Health Research

This publication has 31 references indexed in Scilit: